Greywolf Therapeutics secured US composition-of-matter patent protection for GRWD0715.

Many diseases are caused, or resist treatment, because T cells can't recognize or target cells correctly.​ Our first-in-class small molecules are developed to control T cell activation by modulating antigen presentation, altering how cells appear to the immune system so it can recognize and target them correctly. Our oncology treatment (GRWD5769) is delivering promising Phase 1/2 data in patients with solid tumors, demonstrating a strong safety and tolerability profile, as well as generating meaningful clinical activity. Our autoimmunity treatment (GRWD0715) is progressing in a Phase 1/2 trial to treat the source of axial spondyloarthritis ahead of a planned expansion into other autoimmune indications. Greywolf is headquartered in Oxford, UK.